Featured
Enveric Biosciences Company Overview Video
October 21, 2022
NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
May 11, 2022
https://www.benzinga.com/markets/cannabis/22/05/27124788/exclusive-nasdaq-listed-enveric-to-split-into-two-companies-one-for-cannabinoids-one-for-psyched
CEO Update: Enveric to Spin-off and Dividend Cannabinoid Pipeline to Shareholders
May 11, 2022
CEO Update: Enveric to Spin-off and Dividend Cannabinoid Pipeline to Shareholders Dr. Joseph Tucker, CEO of Enveric Biosciences, details the Company’s plan to spin-off its #cannabinoid clinical development pipeline assets to a wholly-owned subsidiary, Acanna Therapeutics Inc. Following the spin-off, the resulting stand-alone public companies will focus their resources on the R&D of each […]
Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]
March 31, 2022
The Psybrary™: Library of Novel Derivative Molecules Based on Classic Psychedelics
September 28, 2021
Enveric Biosciences – The Psybrary Enveric is focused on creating a library of novel derivative molecules based on classic psychedelics.